Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 498Rectal Neoplasms 268Colonic Neoplasms 219Pancreatic Neoplasms 190Stomach Neoplasms 183Esophageal Neoplasms 135Breast Neoplasms 119Neoplasm Metastasis 117Squamous Cell Carcinoma of Head and Neck 95Head and Neck Neoplasms 92Neoplasms 90Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 62Carcinoma, Hepatocellular 56Adenocarcinoma 40Nasopharyngeal Carcinoma 35Cholangiocarcinoma 33Biliary Tract Neoplasms 27Anus Neoplasms 26Gastrointestinal Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma, Non-Small-Cell Lung 25Keratosis, Actinic 23Gallbladder Neoplasms 22Liver Neoplasms 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 20Bile Duct Neoplasms 19Ovarian Neoplasms 16Carcinoma 16

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3trastuzumab deruxtecan 2tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Fluorouracil × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡